Dale Watt

Mr. Dale Watt

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Cancer Cell
Verified
Journal Article
Open access
CHColin Hutton
Colin Hutton
FHFelix Heider
Felix Heider
ABAdrian Blanco-Gomez
Adrian Blanco-Gomez
ABAntonia Banyard
Antonia Banyard
AKAlexander Kononov
Alexander Kononov
CJClaus Jørgensen
Claus Jørgensen
Fibroblasts display extensive transcriptional heterogeneity, yet functional annotation and characterization of their heterocellular relationships remains incomplete. Using mass cytometry, we chart the stromal composition of 18 murine tissues and 5 spontaneous tumor models, with an emphasis on mesenchymal phenotypes. This analysis reveals extensive stromal heterogeneity across tissues and tumors, and identifies coordinated relationships between mesenchymal and immune cell subsets in pancreatic ductal adenocarcinoma. Expression of CD105 demarks two stable and functionally distinct pancreatic fibroblast lineages, which are also identified in murine and human healthy tissues and tumors. Whereas CD105-positive pancreatic fibroblasts are permissive for tumor growth in vivo, CD105-negative fibroblasts are highly tumor suppressive. This restrictive effect is entirely dependent on functional adaptive immunity. Collectively, these results reveal two functionally distinct pancreatic fibroblast lineages and highlight the importance of mesenchymal and immune cell interactions in restricting tumor growth.

23 July 2025 in EMBO Reports
Verified
Journal Article
Open access
DWDeclan Whyte
Declan Whyte
SFSophie L Fisher
Sophie L Fisher
CMChristopher G J McKenzie
Christopher G J McKenzie
DSDavid Sumpton
David Sumpton
SDSandeep Dhayade
Sandeep Dhayade
Cassie Jemma ClarkeCassie Jemma Clarke
Cassie Jemma Clarke
Understanding mechanisms that facilitate early events in metastatic seeding is key to developing therapeutic approaches to reduce metastasis. Here we identify uracil as a metastasis-associated metabolite in genetically engineered mouse models of cancer and in patients with metastatic breast cancer. Uracil is generated by the enzyme uridine phosphorylase-1 (UPP1), and we find that neutrophils are a significant source of UPP1 in metastatic cancer. Mammary tumours increase expression of adhesion molecules on the neutrophil surface, in a UPP1-dependent manner, leading to decreased neutrophil motility in the pre-metastatic lung. UPP1-expressing neutrophils suppress T-cell proliferation, and the UPP1 product uracil increases fibronectin deposition in the extracellular microenvironment. Knockout or inhibition of UPP1 in mice with mammary tumours increases T-cell numbers and reduces fibronectin content in the lung, and decreases the proportion of mice that develop lung metastasis. These data indicate that UPP1 influences neutrophil behaviour and extracellular matrix deposition in the lung, and suggest that circulating uracil could be a marker of metastasis, and that pharmacological inhibition of UPP1 could be a strategy to reduce recurrence.

4 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
DWDale Watt
Dale Watt
JMJennifer P Morton
Jennifer P Morton
Pancreatic ductal adenocarcinoma is an aggressive disease for which there are very few available therapies. It is notable for its high degree of tumour complexity, with the tumour microenvironment often accounting for the majority of the tumour volume. Until recently, the biology of the stroma was poorly understood, particularly in terms of heterogeneity. Recent research, however, has shed light on the intricacy of signalling within the stroma and particularly the molecular and functional heterogeneity of the cancer associated fibroblasts. In this review, we summarise the recent improvements in our understanding of the different fibroblast populations within PDAC, with a focus on the role TGFβ plays to dictate their formation and function. These studies have highlighted some of the reasons for the failure of trials targeting the tumour stroma, however, there are still considerable gaps in our knowledge, and more work is needed to make effective fibroblast targeting a reality in the clinic.

16 October 2024 in Cancer Research
Verified
Journal Article
Open access
PDF file
SFSigrid K. Fey
Sigrid K. Fey
ANArafath K. Najumudeen
Arafath K. Najumudeen
DWDale Watt
Dale Watt
LMLaura M. Millett
Laura M. Millett
CFCatriona A. Ford
Catriona A. Ford
OSOwen Sansom
Owen Sansom
Pancreatic cancer is characterized by the prevalence of oncogenic mutations in KRAS. Previous studies have reported that altered KRAS gene dosage drives progression and metastasis in pancreatic cancer. Whereas the role of oncogenic KRAS mutations is well characterized, the relevance of the partnering wild-type (WT) KRAS allele in pancreatic cancer is less well understood and controversial. Using in vivo mouse modeling of pancreatic cancer, we demonstrated that WT KRAS restrains the oncogenic impact of mutant KRAS and dramatically impacts both KRAS-mediated tumorigenesis and therapeutic response. Mechanistically, deletion of WT Kras increased oncogenic KRAS signaling through the downstream MAPK effector pathway, driving pancreatic intraepithelial neoplasia initiation. In addition, in the KPC mouse model, a more aggressive model of pancreatic cancer, lack of WT KRAS led to accelerated initiation but delayed tumor progression. These tumors had altered stroma and an enrichment of immunogenic gene signatures. Importantly, loss of WT Kras sensitized Kras mutant tumors to MEK1/2 inhibition though tumors eventually became resistant and then rapidly progressed. This study demonstrates the repressive role of WT KRAS during pancreatic tumorigenesis and highlights the critical impact of the presence of WT KRAS in both tumor progression and therapeutic response in pancreatic cancer. Significance: KRAS allelic status impacts pancreatic cancer progression and has the potential to guide effective treatment in a substantial subset of patients.

20 March 2025 in JHEP Reports
Verified
Journal Article
Open access
CWCeline I. Wittke
Celine I. Wittke
ECEric C. Cheung
Eric C. Cheung
DADimitris Athineos
Dimitris Athineos
NCNicola Clements
Nicola Clements
LBLiam Butler
Liam Butler
THTimothy J. Humpton
Timothy J. Humpton
TP53 is a potent tumour suppressor that coordinates diverse stress response programmes, ranging from pro-survival activities to cell death. p53 is also engaged during tissue damage and repair, including within the liver. Metabolic dysfunction-associated steatohepatitis (MASH) is a major driver of hepatocellular carcinoma, but our understanding of the molecular determinants of MASH remains incomplete. Here, we investigate p53 activity throughout MASH development, with implications for disease prevention. This study utilises non-invasive imaging of p53 activity and liver-specific p53 deletion within the context of mouse models of diet and genetically induced MASH. Histopathological analyses are employed to monitor differential disease progression. Molecular mechanisms are assessed within an in vitro obesogenic system utilising western blotting and flow cytometry. Human relevance is examined through transcriptomic analyses of patients with MASH. Using a p53 reporter mouse, we report early and sustained activation of hepatic p53 in response to a high-fat and high-sugar diet (p <0.05 at 100 days in males, p <0.001 at 200 days in females). Liver-specific loss of p53 accelerates progression of benign fatty liver disease to MASH, which is characterised by high levels of reactive oxygen species, extensive fibrosis, and chronic inflammation (all p <0.0001, n = 13 per high-fat high-sugar group). Our findings indicate that p53 induces the antioxidant gene TP53-induced glycolysis and apoptosis regulator (TIGAR) in vivo and in vitro. We show that loss of TIGAR exacerbates lipid peroxidation during MASH development in vivo (p <0.001) and that TIGAR is engaged in human MASH (p <0.001). Our work demonstrates an important role for the p53-TIGAR axis in protecting against MASH and implicates redox control as a barrier against disease progression that is therapeutically targetable. p53 is of intense interest as a potent tumour suppressor and compounds targeting the pathway have been developed and trialled as anti-cancer therapies. Our findings suggest that early activation of p53 is similarly protective against metabolic dysfunction-associated steatohepatitis and that redox control is an important mediator of this protection. Further studies evaluating the efficacy of proactive activation of p53 in the liver to prevent metabolic dysfunction-associated steatohepatitis, or administration of targeted antioxidants to augment p53 redox protection, could provide new treatment approaches for a condition with few approved therapies.

17 June 2026
Verified
Other
Open access
SFSigrid K. Fey
Sigrid K. Fey
ANArafath K. Najumudeen
Arafath K. Najumudeen
DWDale Watt
Dale Watt
LMLaura M. Millett
Laura M. Millett
CFCatriona A. Ford
Catriona A. Ford
OSOwen Sansom
Owen Sansom
Late-stage intervention with MEK1/2 inhibition improves survival of KPC KrasG12D/fl mice. A, Experimental schematic. KPC KrasG12D/+ and KPC KrasG12D/fl mice were palpated for tumor burden, with palpable tumor burden confirmed by ultrasound imaging, with mice treated continuously from the following day with either vehicle or AZD6244. Tumor growth was monitored by ultrasound imaging once weekly to clinical endpoint. B, Relative volume of pancreatic tumors arising in KPC KrasG12D/+ and KPC KrasG12D/fl mice treated with either vehicle control or AZD6244 from palpable tumor and aged to clinical endpoint. Tumor volume was measured once weekly by high-resolution ultrasound imaging. Each line represents an individual mouse of the indicated genotype and treatment. KPC KrasG12D/fl vehicle, n = 6; KPC KrasG12D/fl AZD6244, n = 7; KPC KrasG12D/+ vehicle, n = 6; KPC KrasG12D/+ AZD6244, n = 4. FC, fold change. C, Change of tumor volume (mm3) of KPC KrasG12D/+ and KPC KrasG12D/fl mice treated with either vehicle control or AZD6244 from palpable tumor between initial ultrasound measurement and a secondary ultrasound measurement (between 6 and 13 days later). Plot represents Log2(FC) of tumor volume between first and second measurements for the full treatment cohort when more than one imaging session was possible. KPC KrasG12D/fl vehicle, n = 5; KPC KrasG12D/fl AZD6244, n = 7; KPC KrasG12D/+ vehicle, n = 4; KPC KrasG12D/+ AZD6244, n = 4. D, Kaplan–Meier survival curves for KPC KrasG12D/+ and KPC KrasG12D/fl mice treated with vehicle or AZD6244, as indicated, from palpable tumor burden and aged to clinical endpoint. KPC KrasG12D/fl vehicle, n = 5; KPC KrasG12D/fl AZD6244, n = 8; KPC KrasG12D/+ vehicle, n = 6; KPC KrasG12D/+ AZD6244, n = 5. MS, median survival. E, Representative hematoxylin and eosin images of tumors from KPC KrasG12D/+ and KPC KrasG12D/fl mice treated with vehicle or AZD6244, as indicated, from palpable tumor burden and aged until clinical endpoint. Representative of five mice per group. Scale bar, 500 μm. F, Left, volcano plot for differentially expressed genes of KPC KrasG12D/+ tumors treated with vehicle or AZD6244 from palpable tumor burden to clinical endpoint. Right, volcano plot for differentially expressed genes of KPC KrasG12D/fl tumors treated with vehicle or AZD6244 from palpable tumor burden to clinical endpoint. Red, significantly altered genes. G, Schematic representing relative impact of WT Kras deletion upon tumur outgrowth and therapeutic responses from KPC KrasG12D/+ and KrasG12D/fl comparison.